Miranda E. Orr

Journal of Clinical Investigation · 2022

⊕ Open access · CC-BY

Biological aging processes underlying cognitive decline and neurodegenerative disease

▲ 356

Nature Medicine · 2023

⊕ Preprint · OA

Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial

▲ 261

The Journal of Prevention of Alzheimer s Disease · 2021

⊕ Open access · OA

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial

▲ 192

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2015

⊕ Preprint · OA

Age-related changes in the proteostasis network in the brain of the naked mole-rat: Implications promoting healthy longevity

▲ 77

Nature Reviews Drug Discovery · 2024

⊕ Preprint · OA

Therapeutic targeting of senescent cells in the CNS

▲ 55

The Journal of Prevention of Alzheimer s Disease · 2023

⊕ Open access · CC-BY

Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics

▲ 51

GeroScience · 2023

⊕ Preprint · OA

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

▲ 41

Research Square · 2023

⊕ Preprint · CC-BY

Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease

▲ 37

Neurotherapeutics · 2025

⊕ Open access · CC-BY

Senescent brain cell types in Alzheimer's disease: Pathological mechanisms and therapeutic opportunities

▲ 20

Journal of Neurochemistry · 2015

⊕ Open access · OA

Metabolic clues to salubrious longevity in the brain of the longest‐lived rodent: the naked mole‐rat

▲ 18

Aging Cell · 2024

⊕ Open access · CC-BY

An interpretable machine learning‐based cerebrospinal fluid proteomics clock for predicting age reveals novel insights into brain aging

▲ 12

Alzheimer s & Dementia · 2020

⊕ Open access · OA

A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes

▲ 10

Research Square · 2024

⊕ Preprint · CC-BY

Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease

▲ 8

Journal of Alzheimer s Disease · 2024

⊕ Preprint · OA

A Need for Refined Senescence Biomarkers and Measures of Senolytics in the Brain

▲ 5